PharmAthene Inc. raised $50 million in its Series B round of financing. The Annapolis, Md.-based company, which is developing products to fight bioterrorism, plans to apply a portion of the funds to continue its development of ToxBlox, an inhibitor of anthrax toxin. (BioWorld Today)
PharmAthene Inc. raised $50 million in its Series B round of financing. The Annapolis, Md.-based company, which is developing products to fight bioterrorism, plans to apply a portion of the funds to continue its development of ToxBlox, an inhibitor of anthrax toxin. (BioWorld Today)
AtheroGenics Inc. saw its share value skyrocket on positive clinical trial results that revealed its lead drug candidate cut plaque buildup in heart disease patients. (BioWorld Today)
